Trial Outcomes & Findings for A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients (NCT NCT01328093)
NCT ID: NCT01328093
Last Updated: 2022-09-07
Results Overview
Mixed model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) mean and standard error. LS mean values were adjusted for baseline, treatment, gender, pooled investigator, visit, prior olanzapine use, treatment-by-visit interaction and baseline-by-visit interaction.
TERMINATED
PHASE3
678 participants
Baseline, 24 weeks
2022-09-07
Participant Flow
This study consisted of a 24-week Double-Blind Active Treatment Phase and was followed by a 28-week Open-Label Active Treatment Phase. Modified intent-to-treat (mITT) is all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
Participant milestones
| Measure |
LY2140023-DB / LY2140023-OL
40 milligrams (mg) LY2140023 administered orally, twice daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily.
40mg LY2140023 administered orally, twice daily for 28 weeks during the Open -Label (OL) Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily.
|
Aripiprazole-DB / LY2140023-OL
15 mg aripiprazole administered orally, once daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 10 mg once daily or 30 mg once daily.
40mg LY2140023 administered orally, twice daily for 28 weeks during the Open -Label (OL) Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily.
|
|---|---|---|
|
Double-Blind Phase
STARTED
|
516
|
162
|
|
Double-Blind Phase
Received at Least 1 Dose of Study Drug
|
514
|
161
|
|
Double-Blind Phase
Modified Intent-To-Treat (mITT)
|
511
|
161
|
|
Double-Blind Phase
COMPLETED
|
231
|
84
|
|
Double-Blind Phase
NOT COMPLETED
|
285
|
78
|
|
Open-Label Phase
STARTED
|
200
|
73
|
|
Open-Label Phase
Received at Least 1 Dose of Study Drug
|
198
|
73
|
|
Open-Label Phase
Modified Intent-To-Treat (mITT)
|
197
|
73
|
|
Open-Label Phase
COMPLETED
|
60
|
23
|
|
Open-Label Phase
NOT COMPLETED
|
140
|
50
|
Reasons for withdrawal
| Measure |
LY2140023-DB / LY2140023-OL
40 milligrams (mg) LY2140023 administered orally, twice daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily.
40mg LY2140023 administered orally, twice daily for 28 weeks during the Open -Label (OL) Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily.
|
Aripiprazole-DB / LY2140023-OL
15 mg aripiprazole administered orally, once daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 10 mg once daily or 30 mg once daily.
40mg LY2140023 administered orally, twice daily for 28 weeks during the Open -Label (OL) Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily.
|
|---|---|---|
|
Double-Blind Phase
Adverse Event
|
78
|
15
|
|
Double-Blind Phase
Withdrawal by Subject
|
42
|
14
|
|
Double-Blind Phase
Lost to Follow-up
|
39
|
14
|
|
Double-Blind Phase
Protocol Violation
|
30
|
10
|
|
Double-Blind Phase
Lack of Efficacy
|
55
|
13
|
|
Double-Blind Phase
Sponsor Decision
|
17
|
3
|
|
Double-Blind Phase
Entry Criteria Not Met
|
7
|
5
|
|
Double-Blind Phase
Scheduling conflict
|
8
|
3
|
|
Double-Blind Phase
Subject is moving or has moved
|
8
|
1
|
|
Double-Blind Phase
Death
|
1
|
0
|
|
Open-Label Phase
Sponsor Decision
|
98
|
34
|
|
Open-Label Phase
Protocol Violation
|
8
|
3
|
|
Open-Label Phase
Lost to Follow-up
|
10
|
1
|
|
Open-Label Phase
Adverse Event
|
10
|
4
|
|
Open-Label Phase
Lack of Efficacy
|
5
|
6
|
|
Open-Label Phase
Withdrawal by Subject
|
4
|
1
|
|
Open-Label Phase
Scheduling conflict
|
2
|
1
|
|
Open-Label Phase
Subject is moving or has moved
|
2
|
0
|
|
Open-Label Phase
Entry Criteria Not Met
|
1
|
0
|
Baseline Characteristics
A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients
Baseline characteristics by cohort
| Measure |
LY2140023-DB
n=511 Participants
40 milligrams (mg) LY2140023 administered orally, twice daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily.
|
Aripiprazole-DB
n=161 Participants
15 mg aripiprazole administered orally, once daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 10 mg once daily or 30 mg once daily.
|
Total
n=672 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
42.29 years
STANDARD_DEVIATION 10.86 • n=99 Participants
|
42.95 years
STANDARD_DEVIATION 10.95 • n=107 Participants
|
42.45 years
STANDARD_DEVIATION 10.88 • n=206 Participants
|
|
Sex: Female, Male
Female
|
185 Participants
n=99 Participants
|
55 Participants
n=107 Participants
|
240 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
326 Participants
n=99 Participants
|
106 Participants
n=107 Participants
|
432 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
73 Participants
n=99 Participants
|
23 Participants
n=107 Participants
|
96 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
438 Participants
n=99 Participants
|
138 Participants
n=107 Participants
|
576 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
6 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
6 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Asian
|
3 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Black or African American
|
238 Participants
n=99 Participants
|
64 Participants
n=107 Participants
|
302 Participants
n=206 Participants
|
|
Race (NIH/OMB)
White
|
259 Participants
n=99 Participants
|
93 Participants
n=107 Participants
|
352 Participants
n=206 Participants
|
|
Race (NIH/OMB)
More than one race
|
5 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
9 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Region of Enrollment
France
|
21 participants
n=99 Participants
|
6 participants
n=107 Participants
|
27 participants
n=206 Participants
|
|
Region of Enrollment
United States
|
341 participants
n=99 Participants
|
112 participants
n=107 Participants
|
453 participants
n=206 Participants
|
|
Region of Enrollment
Puerto Rico
|
27 participants
n=99 Participants
|
6 participants
n=107 Participants
|
33 participants
n=206 Participants
|
|
Region of Enrollment
Spain
|
19 participants
n=99 Participants
|
6 participants
n=107 Participants
|
25 participants
n=206 Participants
|
|
Region of Enrollment
Belgium
|
13 participants
n=99 Participants
|
3 participants
n=107 Participants
|
16 participants
n=206 Participants
|
|
Region of Enrollment
Poland
|
20 participants
n=99 Participants
|
7 participants
n=107 Participants
|
27 participants
n=206 Participants
|
|
Region of Enrollment
Romania
|
21 participants
n=99 Participants
|
6 participants
n=107 Participants
|
27 participants
n=206 Participants
|
|
Region of Enrollment
Austria
|
6 participants
n=99 Participants
|
2 participants
n=107 Participants
|
8 participants
n=206 Participants
|
|
Region of Enrollment
Germany
|
26 participants
n=99 Participants
|
9 participants
n=107 Participants
|
35 participants
n=206 Participants
|
|
Region of Enrollment
Sweden
|
17 participants
n=99 Participants
|
4 participants
n=107 Participants
|
21 participants
n=206 Participants
|
PRIMARY outcome
Timeframe: Baseline, 24 weeksPopulation: Modified intent-to-treat (mITT) population: All randomized participants who received at least one dose of study drug, had baseline and at least one post-baseline weight measurement, excluding participants from the excluded study site.
Mixed model repeated measures (MMRM) analysis was used to calculate Least Squares (LS) mean and standard error. LS mean values were adjusted for baseline, treatment, gender, pooled investigator, visit, prior olanzapine use, treatment-by-visit interaction and baseline-by-visit interaction.
Outcome measures
| Measure |
LY2140023-DB
n=487 Participants
40 milligrams (mg) LY2140023 administered orally, twice daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily.
|
Aripiprazole-DB
n=155 Participants
15 mg aripiprazole administered orally, once daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 10 mg once daily or 30 mg once daily.
|
|---|---|---|
|
Change From Baseline to 24 Weeks in Body Weight
|
-2.8 kilograms (kg)
Standard Error 0.4
|
0.4 kilograms (kg)
Standard Error 0.6
|
SECONDARY outcome
Timeframe: Baseline up to 24 weeksPopulation: Modified intent-to-treat (mITT) population: All randomized participants who received at least one dose of study drug, had a baseline and at least one post-baseline weight measurement, excluding participants from the excluded study site.
Clinically significant change in body weight is defined as either an increase or decrease in weight of ≥7% from baseline.
Outcome measures
| Measure |
LY2140023-DB
n=488 Participants
40 milligrams (mg) LY2140023 administered orally, twice daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily.
|
Aripiprazole-DB
n=155 Participants
15 mg aripiprazole administered orally, once daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 10 mg once daily or 30 mg once daily.
|
|---|---|---|
|
Percentage of Participants With Clinically Significant Weight Change
≥7% Increase
|
4.1 percentage of participants
|
7.1 percentage of participants
|
|
Percentage of Participants With Clinically Significant Weight Change
≥7% Decrease
|
13.1 percentage of participants
|
3.2 percentage of participants
|
SECONDARY outcome
Timeframe: Baseline, 24 weeksPopulation: Modified intent-to-treat (mITT) population: All randomized participants who received at least one dose of study drug, had a baseline and at least one post-baseline BAS global score measurement, excluding participants from the excluded study site.
The BAS is a 4-item instrument that evaluates akathisia associated with use of antipsychotic medications. Item 4 Global Clinical Assessment of Akathisia is rated on a 6- point scale, with scores range from 0 (no symptoms) to 5 (increased severity of symptoms); Only Item 4 was analyzed and presented. The Mixed Model Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and standard error. LS mean values were adjusted for baseline, treatment, gender, pooled investigative site, visit, predefined subpopulation, treatment-by-visit interaction and baseline-by-visit interaction.
Outcome measures
| Measure |
LY2140023-DB
n=455 Participants
40 milligrams (mg) LY2140023 administered orally, twice daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily.
|
Aripiprazole-DB
n=141 Participants
15 mg aripiprazole administered orally, once daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 10 mg once daily or 30 mg once daily.
|
|---|---|---|
|
Change From Baseline up to 24 Weeks in Barnes Akathisia Scale (BAS)
|
0.00 units on a scale
Standard Error 0.03
|
-0.04 units on a scale
Standard Error 0.04
|
SECONDARY outcome
Timeframe: Baseline, 24 weeksPopulation: Modified intent-to-treat (mITT) population: All randomized participants who received at least one dose of study drug, had a baseline and at least one post-baseline SAS total score measurement, excluding participants from the excluded study site.
The SAS is used to measure Parkinsonian-type symptoms in participants exposed to antipsychotics. SAS consists of 10 items, each rated on a 5-point scale: 0 (complete absence of the condition) to 4 (presence of the condition in extreme form). The SAS Total Score is obtained by adding the ten items, and ranges from 0 to 40. Higher scores indicate greater severity of illness. The Mixed Model Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and standard error. LS mean values were adjusted for baseline, treatment, gender, pooled investigative site, visit, predefined subpopulation, treatment by-visit-interaction and baseline-by-visit interaction.
Outcome measures
| Measure |
LY2140023-DB
n=456 Participants
40 milligrams (mg) LY2140023 administered orally, twice daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily.
|
Aripiprazole-DB
n=141 Participants
15 mg aripiprazole administered orally, once daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 10 mg once daily or 30 mg once daily.
|
|---|---|---|
|
Change From Baseline up to 24 Weeks in Simpson-Angus Scale (SAS)
|
-0.17 units on a scale
Standard Error 0.06
|
-0.20 units on a scale
Standard Error 0.08
|
SECONDARY outcome
Timeframe: Baseline, 24 weeksPopulation: Modified intent-to-treat (mITT) population: All randomized participants who received at least one dose of study drug, had a baseline and at least one post-baseline AIMS 1-7 Total Score measurement, excluding participants from the excluded study site.
AIMS is a 12-item scale designed to record the occurrence of dyskinetic movements. Items 1 to 10 are rated on a 5- point scale: 0 (no dyskinetic movements) to 4 (severe dyskinetic movements). Items 11 and 12 are yes/no questions regarding the dental condition of a participant. The AIMS 1-7 Total Score is the sum of Items 1 through 7 of the AIMS, and ranges from 0 to 28. Higher scores indicate greater severity of illness. Only AIMS 1-7 Total Score was analyzed and presented. The Mixed Model Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and standard error. LS mean values were adjusted for baseline, treatment, gender, pooled investigative site, visit, predefined subpopulation, treatment-by-visit interaction and baseline-by-visit interaction.
Outcome measures
| Measure |
LY2140023-DB
n=456 Participants
40 milligrams (mg) LY2140023 administered orally, twice daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily.
|
Aripiprazole-DB
n=141 Participants
15 mg aripiprazole administered orally, once daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 10 mg once daily or 30 mg once daily.
|
|---|---|---|
|
Change From Baseline up to 24 Weeks in Abnormal Involuntary Movement Scale (AIMS)
|
-0.11 units on a scale
Standard Error 0.05
|
-0.10 units on a scale
Standard Error 0.07
|
SECONDARY outcome
Timeframe: Baseline, 24 weeksPopulation: Modified intent-to-treat (mITT) population: All randomized participants who received at least one dose of study drug, had a baseline and at least one post-baseline PANSS measurement, excluding participants from the excluded study site.
The PANSS consists of 30 items and 3 subscales and is designed to measure severity of psychopathology in schizophrenia. The PANSS Positive Subscale and the PANSS Negative Subscale each contain 7 items, and the remaining 16 items make up the PANSS General Psychopathology Subscale. Each item is rated from 1 (symptom not present) to 7 (symptom extremely severe). The PANSS Total Score is the sum of the 30 items, with scores range from 30 to 210. The PANSS Positive Subscale and PANSS Negative Subscale scores each range from 7 to 49. The PANSS General Psychopathology subscale score ranges from 16 to 112. Higher scores indicate greater severity of illness. The Mixed Model Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and 95% confidence interval. LS mean values were adjusted for baseline, treatment, gender, pooled investigative site, visit, predefined subpopulation, treatment-by-visit interaction and baseline-by-visit interaction.
Outcome measures
| Measure |
LY2140023-DB
n=482 Participants
40 milligrams (mg) LY2140023 administered orally, twice daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily.
|
Aripiprazole-DB
n=155 Participants
15 mg aripiprazole administered orally, once daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 10 mg once daily or 30 mg once daily.
|
|---|---|---|
|
Change From Baseline up to 24 Weeks in Positive and Negative Syndrome Scale (PANSS) Total and Subscale Scores
PANSS Total Score
|
-12.03 units on a scale
Standard Error 0.99
|
-15.58 units on a scale
Standard Error 1.58
|
|
Change From Baseline up to 24 Weeks in Positive and Negative Syndrome Scale (PANSS) Total and Subscale Scores
PANSS Positive Score
|
-3.40 units on a scale
Standard Error 0.32
|
-4.62 units on a scale
Standard Error 0.50
|
|
Change From Baseline up to 24 Weeks in Positive and Negative Syndrome Scale (PANSS) Total and Subscale Scores
PANSS Negative Score
|
-2.98 units on a scale
Standard Error 0.31
|
-3.34 units on a scale
Standard Error 0.48
|
|
Change From Baseline up to 24 Weeks in Positive and Negative Syndrome Scale (PANSS) Total and Subscale Scores
PANSS General Psychopathology Score
|
-5.80 units on a scale
Standard Error 0.56
|
-7.85 units on a scale
Standard Error 0.89
|
SECONDARY outcome
Timeframe: Baseline, 24 weeksPopulation: Modified intent-to-treat (mITT) population: All randomized participants who received at least one dose of study drug, had a baseline and at least one post-baseline VAS health state measurement, excluding participants from the excluded study site.
The EQ-5D is a generic, multidimensional, health-related, quality-of-life instrument that contains 2 parts: a health status profile and a visual analog scale (VAS) to rate global health-related quality of life. VAS health state scores range from 0 (worst imaginable health state) to 100 (best imaginable health state). The Mixed Model Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and standard error. LS mean values were adjusted for baseline, treatment, gender, pooled investigative site, visit, predefined subpopulation, treatment-by-visit interaction and baseline-by-visit interaction.
Outcome measures
| Measure |
LY2140023-DB
n=386 Participants
40 milligrams (mg) LY2140023 administered orally, twice daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily.
|
Aripiprazole-DB
n=126 Participants
15 mg aripiprazole administered orally, once daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 10 mg once daily or 30 mg once daily.
|
|---|---|---|
|
Change From Baseline up to 24 Weeks in EuroQol-5 Dimensions Questionnaire (EQ-5D) Visual Analog Scale (VAS) Health State Score
|
4.2 units on a scale
Standard Error 1.4
|
3.1 units on a scale
Standard Error 2.0
|
SECONDARY outcome
Timeframe: Baseline to 24 weeksPopulation: Modified intent-to-treat (mITT) population: All randomized participants who received at least one dose of study drug and had S-RUM assessment, excluding participants from the excluded study site. Last observation carried forward (LOCF) principle was used.
The S-RUM is a 31-item questionnaire to assess the participant's occupation (work and home), living arrangements, encounters with law enforcement, victimization, ER visits, and outpatient medical visits for a specified period of time. Item 1 asks about the number of ER or equivalent facility visits a participant had for psychiatric (psych) illness. Item 2 asks about the number of ER or equivalent facility visits a participant had for non-psychiatric (non-psych) illness or injury. Item 5 asks about the number of outpatient visits to other physicians (not psychiatrists or dentists). Analysis of variance (ANOVA) was used to calculate Least Squares (LS) mean and standard error. LS mean values were adjusted for pooled investigator, gender and treatment.
Outcome measures
| Measure |
LY2140023-DB
n=451 Participants
40 milligrams (mg) LY2140023 administered orally, twice daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily.
|
Aripiprazole-DB
n=146 Participants
15 mg aripiprazole administered orally, once daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 10 mg once daily or 30 mg once daily.
|
|---|---|---|
|
Schizophrenia Resource Utilization Module (S-RUM) - Number of Emergency Room (ER) or Equivalent Facility Visits and Outpatient Medical Visits
ER/Facility (Psych) visits
|
0.06 visits
Standard Error 0.01
|
0.04 visits
Standard Error 0.02
|
|
Schizophrenia Resource Utilization Module (S-RUM) - Number of Emergency Room (ER) or Equivalent Facility Visits and Outpatient Medical Visits
ER/Facility (Non-Psych) visits
|
0.06 visits
Standard Error 0.01
|
0.02 visits
Standard Error 0.02
|
|
Schizophrenia Resource Utilization Module (S-RUM) - Number of Emergency Room (ER) or Equivalent Facility Visits and Outpatient Medical Visits
Outpatient (Non-Psych or Dentist) visits
|
0.28 visits
Standard Error 0.04
|
0.30 visits
Standard Error 0.06
|
SECONDARY outcome
Timeframe: Baseline to 24 weeksPopulation: Modified intent-to-treat (mITT) population: All randomized participants who received at least one dose of study drug and had S-RUM assessment, excluding participants from the excluded study site. Last observation carried forward (LOCF) principle was used.
The S-RUM is a 31-item questionnaire to assess the participant's occupation (work and home), living arrangements, encounters with law enforcement, victimization, emergency room (ER) visits, and outpatient medical visits for a specified period of time. Item 4 asks about the number of sessions with a psychiatrist a participant had. Analysis of variance (ANOVA) was used to calculate Least Squares (LS) mean and standard error. LS mean values were adjusted for pooled investigator, gender and treatment.
Outcome measures
| Measure |
LY2140023-DB
n=451 Participants
40 milligrams (mg) LY2140023 administered orally, twice daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily.
|
Aripiprazole-DB
n=146 Participants
15 mg aripiprazole administered orally, once daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 10 mg once daily or 30 mg once daily.
|
|---|---|---|
|
Schizophrenia Resource Use Module (S-RUM) - Number of Sessions With a Psychiatrist
|
0.39 sessions
Standard Error 0.07
|
0.41 sessions
Standard Error 0.11
|
SECONDARY outcome
Timeframe: Baseline, 24 weeksPopulation: Modified intent-to-treat (mITT) population: All randomized participants who received at least one dose of study drug, had a baseline and at least one post-baseline SWN-SF Total Score measurement, excluding participants from the excluded study site.
The SWN-SF measures subjective well-being of the participant for the previous 7 days. The 20-item scale covers 5 health domains (subscales; 4 items each): emotional regulation, self-control, mental functioning, social integration, and physical functioning. Individual scores range from 1 (not at all) to 6 (very much). Each of the 5 subscale scores range from 4 to 24. SWN-SF Total Scores range from 20 to 120. Higher scores indicate greater well-being. The Mixed Model Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and standard error. LS mean values were adjusted for baseline, treatment, gender, pooled investigative site, visit, predefined subpopulation, treatment-by-visit interaction and baseline-by-visit interaction.
Outcome measures
| Measure |
LY2140023-DB
n=423 Participants
40 milligrams (mg) LY2140023 administered orally, twice daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily.
|
Aripiprazole-DB
n=133 Participants
15 mg aripiprazole administered orally, once daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 10 mg once daily or 30 mg once daily.
|
|---|---|---|
|
Change From Baseline up to 24 Weeks in Subjective Well-Being Under Neuroleptic Treatment Scale- Short Form (SWN-SF) Total Score
|
4.6 units on a scale
Standard Error 1.0
|
5.3 units on a scale
Standard Error 1.5
|
SECONDARY outcome
Timeframe: Baseline, 24 weeksPopulation: Modified intent-to-treat (mITT) population: All randomized participants who received at least one dose of study drug, had a baseline and at least one post-baseline PSP measurement, excluding participants from the excluded study site.
The PSP scale is a 100-point (minimum 1, maximum 100), single item, clinician-rated scale to assess a participant's overall functioning, including personal and social relationships, socially useful activities, self-care, and disturbing and aggressive behaviors. Higher scores indicate a higher level of functioning. The Mixed Model Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and standard error. LS mean values were adjusted for baseline, treatment, gender, pooled investigative site, visit, predefined subpopulation, treatment-by-visit interaction and baseline-by-visit interaction.
Outcome measures
| Measure |
LY2140023-DB
n=431 Participants
40 milligrams (mg) LY2140023 administered orally, twice daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily.
|
Aripiprazole-DB
n=136 Participants
15 mg aripiprazole administered orally, once daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 10 mg once daily or 30 mg once daily.
|
|---|---|---|
|
Change From Baseline up to 24 Weeks in Personal and Social Performance (PSP) Score
|
5.9 units on a scale
Standard Error 0.7
|
6.4 units on a scale
Standard Error 1.1
|
SECONDARY outcome
Timeframe: Baseline, 24 weeksPopulation: Modified intent-to-treat (mITT) population: All randomized participants who received at least one dose of study drug, had a baseline and at least one post-baseline CGI-S measurement, excluding participants from the excluded study site.
The CGI-S instrument is used to record the severity of mental illness at the time of assessment. The score ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill). Higher scores indicate greater severity of illness. The Mixed Model Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and standard error. LS mean values were adjusted for baseline, treatment, gender, pooled investigative site, visit, predefined subpopulation, treatment-by-visit interaction and baseline-by-visit interaction.
Outcome measures
| Measure |
LY2140023-DB
n=487 Participants
40 milligrams (mg) LY2140023 administered orally, twice daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily.
|
Aripiprazole-DB
n=155 Participants
15 mg aripiprazole administered orally, once daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 10 mg once daily or 30 mg once daily.
|
|---|---|---|
|
Change From Baseline up to 24 Weeks in Clinical Global Impression-Severity Scale (CGI-S)
|
-0.51 units on a scale
Standard Error 0.05
|
-0.69 units on a scale
Standard Error 0.08
|
SECONDARY outcome
Timeframe: Baseline, 24 weeksPopulation: Modified intent-to-treat (mITT) population: All randomized participants who received at least one dose of study drug, had a baseline and at least one post-baseline NSA-16 Total Score measurement, excluding participants from the excluded study site.
The NSA-16 scale is used to help clinicians rate behaviors (not psychopathology) commonly associated with negative symptoms of schizophrenia. The scale rates participants on 16 "anchors". Each item ("anchor") is rated from 1 (better) to 6 (worse). The NSA-16 Total Score is the sum of the 16 specific items and ranges from 16 to 96. Higher scores indicate greater severity of illness. The Mixed Model Repeated Measures (MMRM) analysis was used to calculate Least Squares (LS) mean and standard error. LS mean values were adjusted for baseline, treatment, gender, pooled investigative site, visit, predefined subpopulation, treatment-by-visit interaction and baseline-by-visit interaction.
Outcome measures
| Measure |
LY2140023-DB
n=431 Participants
40 milligrams (mg) LY2140023 administered orally, twice daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily.
|
Aripiprazole-DB
n=136 Participants
15 mg aripiprazole administered orally, once daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 10 mg once daily or 30 mg once daily.
|
|---|---|---|
|
Change From Baseline up to 24 Weeks in 16-Item Negative Symptom Assessment (NSA-16)
|
-6.22 units on a scale
Standard Error 0.68
|
-6.37 units on a scale
Standard Error 1.03
|
SECONDARY outcome
Timeframe: Baseline up to 24 weeksPopulation: Modified intent-to-treat (mITT) population: All randomized participants who received at least one dose of study drug, had a baseline and at least one post-baseline PANSS measurement, excluding participants from the excluded study site. Last observation carried forward (LOCF) principle was used.
The PANSS assesses the positive symptoms, negative symptoms, and general psychopathology specifically associated with schizophrenia. The scale consists of 30 items. Each item is rated on a scale from 1 (absence of symptoms) to 7 (symptoms extremely severe). The sum of the 30 items is defined as the PANSS Total Score and ranges from 30 to 210. Higher scores indicate greater severity of illness. Data presented are the number of participants with 30% or greater decrease from baseline in PANSS Total score.
Outcome measures
| Measure |
LY2140023-DB
n=486 Participants
40 milligrams (mg) LY2140023 administered orally, twice daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily.
|
Aripiprazole-DB
n=155 Participants
15 mg aripiprazole administered orally, once daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 10 mg once daily or 30 mg once daily.
|
|---|---|---|
|
Number of Participants With 30% or Greater Decrease in Positive and Negative Syndrome Scale (PANSS) Total Score
|
133 participants
|
49 participants
|
SECONDARY outcome
Timeframe: Baseline to 24 weeksPopulation: Modified intent-to-treat (mITT) population: All randomized participants who received at least one dose of study drug, had a baseline and at least one post-baseline C-SSRS measurement, excluding participants from the excluded study site.
Columbia Suicide Rating Scale (C-SSRS) captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal ideation: a "yes" answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation. Suicidal behavior: a "yes" answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Data presented are the number of participants with treatment-emergent suicidal ideation or behavior during the treatment period (with a change from lead-in baseline in C-SSRS).
Outcome measures
| Measure |
LY2140023-DB
n=488 Participants
40 milligrams (mg) LY2140023 administered orally, twice daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily.
|
Aripiprazole-DB
n=155 Participants
15 mg aripiprazole administered orally, once daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 10 mg once daily or 30 mg once daily.
|
|---|---|---|
|
Number of Participants With Suicidal Behaviors and Ideations Measured by Columbia Suicide Severity Rating Scale (C-SSRS)
Treatment-Emergent Suicidal Ideation
|
46 participants
|
7 participants
|
|
Number of Participants With Suicidal Behaviors and Ideations Measured by Columbia Suicide Severity Rating Scale (C-SSRS)
Treatment-Emergent Suicidal Behavior
|
7 participants
|
0 participants
|
SECONDARY outcome
Timeframe: Randomization up to 24 weeksPopulation: Modified intent-to-treat (mITT) population: All randomized participants who received at least one dose of study drug, excluding participants from the excluded study site. Participants who completed the study were considered censored: 229 for LY2140023 group and 84 for Aripiprazole group.
The time to discontinuation due to any reason was defined as the total number of days between randomization and discontinuation date. The time to discontinuation was analyzed using Kaplan-Meier estimated survival curves. Participants who completed the study were considered censored.
Outcome measures
| Measure |
LY2140023-DB
n=511 Participants
40 milligrams (mg) LY2140023 administered orally, twice daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily.
|
Aripiprazole-DB
n=161 Participants
15 mg aripiprazole administered orally, once daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 10 mg once daily or 30 mg once daily.
|
|---|---|---|
|
Time to Discontinuation
|
140 days
Interval 120.0 to 158.0
|
169 days
Interval 131.0 to
The upper limit was not calculable because an insufficient number of participants reached the event at the final time point for assessment.
|
Adverse Events
LY2140023-DB
Aripiprazole-DB
LY2140023-OL
Serious adverse events
| Measure |
LY2140023-DB
n=511 participants at risk
40 milligrams (mg) LY2140023 administered orally, twice daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily.
|
Aripiprazole-DB
n=161 participants at risk
15 mg aripiprazole administered orally, once daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 10 mg once daily or 30 mg once daily.
|
LY2140023-OL
n=270 participants at risk
40mg LY2140023 administered orally, twice daily for 28 weeks during the Open -Label (OL) Phase, following the treatment with either 40 mg LY2140023 or 15 mg aripiprazole during the Double-Blind Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily.
|
|---|---|---|---|
|
Cardiac disorders
Wolff-parkinson-white syndrome
|
0.00%
0/511
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.62%
1/161 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Gastrointestinal disorders
Ileus
|
0.20%
1/511 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Hepatobiliary disorders
Cholelithiasis
|
0.20%
1/511 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Infections and infestations
Appendicitis
|
0.00%
0/511
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.37%
1/270 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Infections and infestations
Diverticulitis
|
0.20%
1/511 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Injury, poisoning and procedural complications
Alcohol poisoning
|
0.20%
1/511 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Injury, poisoning and procedural complications
Laceration
|
0.00%
0/511
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.37%
1/270 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Injury, poisoning and procedural complications
Ligament rupture
|
0.00%
0/511
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.62%
1/161 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.37%
1/270 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Injury, poisoning and procedural complications
Lower limb fracture
|
0.20%
1/511 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Injury, poisoning and procedural complications
Maternal exposure during pregnancy
|
0.54%
1/185 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/55
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/106
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Injury, poisoning and procedural complications
Tibia fracture
|
0.00%
0/511
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.62%
1/161 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.00%
0/511
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.37%
1/270 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.20%
1/511 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Nervous system disorders
Convulsion
|
0.20%
1/511 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Nervous system disorders
Dizziness
|
0.20%
1/511 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Nervous system disorders
Dystonia
|
0.39%
2/511 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Nervous system disorders
Syncope
|
0.20%
1/511 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Psychiatric disorders
Anxiety
|
0.20%
1/511 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.62%
1/161 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.74%
2/270 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Psychiatric disorders
Anxiety disorder
|
0.20%
1/511 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Psychiatric disorders
Completed suicide
|
0.20%
1/511 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/511
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.37%
1/270 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Psychiatric disorders
Delusion
|
0.00%
0/511
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.74%
2/270 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Psychiatric disorders
Depression
|
0.00%
0/511
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.37%
1/270 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Psychiatric disorders
Hallucination, auditory
|
0.00%
0/511
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.37%
1/270 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Psychiatric disorders
Homicidal ideation
|
0.20%
1/511 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Psychiatric disorders
Psychotic disorder
|
1.6%
8/511 • Number of events 8
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.62%
1/161 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Psychiatric disorders
Schizophrenia
|
2.9%
15/511 • Number of events 16
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.2%
2/161 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.74%
2/270 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Psychiatric disorders
Sleep disorder
|
0.20%
1/511 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Psychiatric disorders
Stress
|
0.20%
1/511 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Psychiatric disorders
Suicidal ideation
|
0.20%
1/511 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Psychiatric disorders
Suicide attempt
|
0.78%
4/511 • Number of events 4
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary thrombosis
|
0.20%
1/511 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Surgical and medical procedures
Hip arthroplasty
|
0.00%
0/511
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.37%
1/270 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Vascular disorders
Hypertensive crisis
|
0.20%
1/511 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Vascular disorders
Shock haemorrhagic
|
0.20%
1/511 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
Other adverse events
| Measure |
LY2140023-DB
n=511 participants at risk
40 milligrams (mg) LY2140023 administered orally, twice daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily.
|
Aripiprazole-DB
n=161 participants at risk
15 mg aripiprazole administered orally, once daily for 24 weeks during the Double-Blind (DB) Phase. Dose was adjustable to 10 mg once daily or 30 mg once daily.
|
LY2140023-OL
n=270 participants at risk
40mg LY2140023 administered orally, twice daily for 28 weeks during the Open -Label (OL) Phase, following the treatment with either 40 mg LY2140023 or 15 mg aripiprazole during the Double-Blind Phase. Dose was adjustable to 20 mg twice daily or 80 mg twice daily.
|
|---|---|---|---|
|
Cardiac disorders
Left atrial dilatation
|
0.20%
1/511 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.1%
3/270 • Number of events 3
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Gastrointestinal disorders
Abdominal discomfort
|
2.5%
13/511 • Number of events 14
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.2%
2/161 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.1%
3/270 • Number of events 3
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Gastrointestinal disorders
Abdominal pain upper
|
2.0%
10/511 • Number of events 10
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.2%
2/161 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.37%
1/270 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Gastrointestinal disorders
Constipation
|
2.7%
14/511 • Number of events 15
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.2%
2/161 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.37%
1/270 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Gastrointestinal disorders
Diarrhoea
|
3.9%
20/511 • Number of events 21
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
5.0%
8/161 • Number of events 9
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.74%
2/270 • Number of events 3
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Gastrointestinal disorders
Dry mouth
|
2.9%
15/511 • Number of events 15
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
3.1%
5/161 • Number of events 5
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.1%
3/270 • Number of events 3
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Gastrointestinal disorders
Dyspepsia
|
0.98%
5/511 • Number of events 5
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
3.7%
6/161 • Number of events 6
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.37%
1/270 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Gastrointestinal disorders
Nausea
|
19.4%
99/511 • Number of events 112
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
11.2%
18/161 • Number of events 19
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
5.6%
15/270 • Number of events 15
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Gastrointestinal disorders
Toothache
|
0.98%
5/511 • Number of events 6
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.9%
3/161 • Number of events 3
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.74%
2/270 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Gastrointestinal disorders
Vomiting
|
8.0%
41/511 • Number of events 58
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
7.5%
12/161 • Number of events 14
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.9%
5/270 • Number of events 8
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
General disorders
Fatigue
|
2.7%
14/511 • Number of events 14
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
3.7%
6/161 • Number of events 6
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
General disorders
Irritability
|
2.2%
11/511 • Number of events 11
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.62%
1/161 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
General disorders
Pyrexia
|
0.39%
2/511 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
2.5%
4/161 • Number of events 5
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.37%
1/270 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
General disorders
Therapeutic response unexpected
|
1.2%
6/511 • Number of events 6
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.2%
2/161 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.74%
2/270 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Infections and infestations
Influenza
|
0.98%
5/511 • Number of events 5
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.2%
2/161 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.37%
1/270 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Infections and infestations
Nasopharyngitis
|
7.4%
38/511 • Number of events 40
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
5.0%
8/161 • Number of events 10
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.9%
5/270 • Number of events 5
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Infections and infestations
Upper respiratory tract infection
|
1.4%
7/511 • Number of events 8
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.2%
2/161 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.37%
1/270 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Injury, poisoning and procedural complications
Excoriation
|
0.39%
2/511 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.9%
3/161 • Number of events 3
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Injury, poisoning and procedural complications
Laceration
|
0.20%
1/511 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.2%
2/161 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.74%
2/270 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Injury, poisoning and procedural complications
Maternal exposure during pregnancy
|
1.1%
2/185 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/55
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.94%
1/106 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Investigations
Aspartate aminotransferase increased
|
1.4%
7/511 • Number of events 7
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Investigations
Blood creatine phosphokinase increased
|
5.7%
29/511 • Number of events 30
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
2.5%
4/161 • Number of events 4
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.1%
3/270 • Number of events 3
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Investigations
Weight decreased
|
1.8%
9/511 • Number of events 9
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.62%
1/161 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.74%
2/270 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Investigations
Weight increased
|
1.8%
9/511 • Number of events 9
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.9%
3/161 • Number of events 3
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.37%
1/270 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
4.3%
22/511 • Number of events 22
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
3.7%
6/161 • Number of events 6
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Metabolism and nutrition disorders
Increased appetite
|
1.8%
9/511 • Number of events 9
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.9%
3/161 • Number of events 3
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
1.8%
9/511 • Number of events 9
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
3.1%
5/161 • Number of events 6
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.74%
2/270 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.39%
2/511 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.9%
3/161 • Number of events 3
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Musculoskeletal and connective tissue disorders
Muscle tightness
|
0.00%
0/511
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.2%
2/161 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.37%
1/270 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
|
0.59%
3/511 • Number of events 3
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.62%
1/161 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.1%
3/270 • Number of events 3
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.20%
1/511 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.2%
2/161 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.74%
2/270 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
1.4%
7/511 • Number of events 8
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.62%
1/161 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.1%
3/270 • Number of events 3
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Nervous system disorders
Akathisia
|
2.5%
13/511 • Number of events 13
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
7.5%
12/161 • Number of events 12
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.74%
2/270 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Nervous system disorders
Disturbance in attention
|
0.59%
3/511 • Number of events 3
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.2%
2/161 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Nervous system disorders
Dizziness
|
3.1%
16/511 • Number of events 16
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
5.0%
8/161 • Number of events 9
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.1%
3/270 • Number of events 3
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Nervous system disorders
Extrapyramidal disorder
|
0.39%
2/511 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.9%
3/161 • Number of events 3
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Nervous system disorders
Headache
|
11.2%
57/511 • Number of events 69
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
6.2%
10/161 • Number of events 10
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
5.9%
16/270 • Number of events 17
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Nervous system disorders
Myoclonus
|
0.78%
4/511 • Number of events 4
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.9%
3/161 • Number of events 3
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.37%
1/270 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Nervous system disorders
Sedation
|
0.78%
4/511 • Number of events 4
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
2.5%
4/161 • Number of events 4
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.74%
2/270 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Nervous system disorders
Somnolence
|
2.9%
15/511 • Number of events 17
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
2.5%
4/161 • Number of events 5
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.74%
2/270 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Nervous system disorders
Tremor
|
1.6%
8/511 • Number of events 10
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.9%
3/161 • Number of events 3
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Psychiatric disorders
Agitation
|
0.39%
2/511 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.2%
2/161 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.37%
1/270 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Psychiatric disorders
Anxiety
|
4.1%
21/511 • Number of events 22
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
5.0%
8/161 • Number of events 8
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
2.2%
6/270 • Number of events 8
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Psychiatric disorders
Bruxism
|
0.39%
2/511 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.2%
2/161 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.37%
1/270 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Psychiatric disorders
Hallucination, auditory
|
0.78%
4/511 • Number of events 4
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.2%
2/161 • Number of events 3
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.37%
1/270 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Psychiatric disorders
Insomnia
|
9.8%
50/511 • Number of events 53
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
11.8%
19/161 • Number of events 20
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
3.0%
8/270 • Number of events 9
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Psychiatric disorders
Restlessness
|
1.8%
9/511 • Number of events 10
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.2%
2/161 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.37%
1/270 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Psychiatric disorders
Schizophrenia
|
2.2%
11/511 • Number of events 12
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.1%
3/270 • Number of events 3
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Reproductive system and breast disorders
Erectile dysfunction
|
0.31%
1/326 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.9%
2/106 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/164
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Respiratory, thoracic and mediastinal disorders
Asthma
|
0.20%
1/511 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.1%
3/270 • Number of events 3
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.78%
4/511 • Number of events 4
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.2%
2/161 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.1%
3/270 • Number of events 3
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.20%
1/511 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.9%
3/161 • Number of events 3
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.74%
2/270 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.39%
2/511 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.9%
3/161 • Number of events 3
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.74%
2/270 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
1.2%
6/511 • Number of events 6
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.62%
1/161 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/270
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
2.2%
11/511 • Number of events 12
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.62%
1/161 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.1%
3/270 • Number of events 3
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Skin and subcutaneous tissue disorders
Rash
|
1.4%
7/511 • Number of events 9
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/161
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.37%
1/270 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Social circumstances
Menopause
|
0.00%
0/185
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.8%
1/55 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/106
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Surgical and medical procedures
Female sterilisation
|
0.00%
0/185
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.8%
1/55 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.00%
0/106
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Surgical and medical procedures
Tooth extraction
|
0.00%
0/511
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
1.2%
2/161 • Number of events 2
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.37%
1/270 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
|
Vascular disorders
Hypertension
|
1.4%
7/511 • Number of events 7
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
2.5%
4/161 • Number of events 4
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
0.37%
1/270 • Number of events 1
Adverse events were reported for all randomized participants who received at least 1 dose of study drug, excluding participants from a Good Clinical Practice (GCP) noncompliant study site.
|
Additional Information
Chief Medical Officer
Eli Lilly and Company
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: GT60